Johnson & Johnson reports trail blazer 1st Quarter results

Johnson & Johnson expects an increase in demand for its cancer drugs.

On Tuesday, Johnson & Johnson first quarterly report beat analysts’ estimate and raised its full-year sales forecast on the strength of a growing demand for its cancer drugs.

J&J raised its full-year sales forecast from the earlier range of $80.6 billion to $81.4 billion to the newer $81.0 billion to $81.8 billion.

Excluding items, the company earned $2.06 per share against the analysts’ average expectation of $2.02 per share.

Sales in the first quarter jumped to $20.01 billion from $17.77 billion a year earlier, beating analysts’ estimates of $19.46 billion.

Net earnings fell to $4.37 billion, or $1.60 per share, from $4.42 billion, or $1.61 per share, a year earlier.

With the news reaching the market, its shares in the Dow-Jones were up by 1.1% to $133.25.

Advertisements


Categories: Creativity, Entrepreneurship, HR & Organization, Strategy

Tags: , , , , , , , , ,

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: